Multiple sclerosis: failure of treatment with verapamil in a pilot trial

Verapamil hydrochloride, a lipophilic calcium channel blocking agent was used in the treatment of 11 patients with multiple sclerosis. The rationale of the therapy was to improve the conduction capacity of the damaged nerve fibres. The therapy did not prove effective in a pilot trial.